We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Despite Lilly’s Phase III Alzheimer’s Stumbles, Analysts Hope for Filing
Despite Lilly’s Phase III Alzheimer’s Stumbles, Analysts Hope for Filing
August 29, 2012
Eli Lilly’s Alzheimer’s disease candidate solanezumab failed to meet its primary endpoints in a pair of closely watched Phase III trials, but flickers of promise seen in mildly affected Alzheimer’s patients have lifted some analysts’ hopes the drug could still be filed for regulatory approval.